Patents by Inventor Stefan Lutz

Stefan Lutz has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Composition comprising a pulmonary surfactant and a pde2 inhibitor
    Publication number: 20060229242
    Abstract: The invention relates to the combined administration of a pulmonary surfactant and a PDE2 inhibitor for the treatment of a disease in which pulmonary surfactant malfunction and/or phosphodiesterase 2 (PDE2) activity is detrimental.
    Type: Application
    Filed: August 27, 2004
    Publication date: October 12, 2006
    Applicant: Altana Phazma AG
    Inventor: Stefan-Lutz Wollin
  • Synergistic combination comprising roflumilast and (r,r) - formoterol
    Publication number: 20060199865
    Abstract: The invention relates to the combined administration of roflumilast and R,R-formoterol for the treatment of respiratory tract disorders.
    Type: Application
    Filed: November 26, 2003
    Publication date: September 7, 2006
    Inventors: Rolf Beume, Christian Weimar, Degenhard Marx, Daniela Bundschuh, Stefan-Lutz Wollin
  • Synergistic combination comprising roflumilast and an anticholinergic agent selected from ipratropium, oxitropium and tiotropium salts for the treatment of respiratory diseases
    Publication number: 20060189642
    Abstract: The invention relates to the administration of roflumilast oral or intravenously and an anticholinergic agent selected from the group of an ipratropium, oxitropium or tiotropium salt for the treatment of respiratory diseases.
    Type: Application
    Filed: March 26, 2004
    Publication date: August 24, 2006
    Applicant: ALTANA PHARMA AG
    Inventors: Daniela Bundschuh, Stefan-Lutz Wollin, Christian Weimar
  • Composition comprising a pulmonary surfactant and a pde5 inhibitor for the treatment of lung diseases
    Publication number: 20060148693
    Abstract: The invention relates to the combined administration of a pulmonary surfactant and a PDE5 inhibitor for the treatment of a disease in which pulmonary surfactant malfunction and/or phosphodiesterase 5 (PDE5) activity is detrimental.
    Type: Application
    Filed: June 15, 2004
    Publication date: July 6, 2006
    Applicant: Altana Pharma AG
    Inventor: Stefan-Lutz Wollin
  • Synergistic combination comprising roflumilast and an anticholinergic agent selected from ipratropium, oxitropium and tiotropium salts for the treatment of respiratory diseases
    Publication number: 20060147382
    Abstract: The invention relates to the administration of roflumilast and an anticholinergic agent selected from the group of an ipratropium, oxitropium or tiotropium salt for the treatment of respiratory diseases.
    Type: Application
    Filed: March 26, 2004
    Publication date: July 6, 2006
    Applicant: Altana Pharma AG
    Inventors: Daniela Bundschuh, Stefan-Lutz Wollin, Christian Weimar
  • Pharmaceutical composition of a pde4 or pde 3/4 inhibitor and histamine receptor antagonist
    Publication number: 20050112069
    Abstract: The invention relates to the combined administration of PDE4 or PDE3/4 inhibitors and histamine receptor antagonists for the treatment of respiratory diseases.
    Type: Application
    Filed: February 25, 2003
    Publication date: May 26, 2005
    Inventors: Rolf Beume, Daniela Bundschuh, Christian Weimar, Stefan-Lutz Wollin
  • Combination
    Publication number: 20050014762
    Abstract: The invention relates to the combined administration of PDE4 or PDE3/4 inhibitors and leukotriene receptor antagonists for the treatment of respiratory tract disorders.
    Type: Application
    Filed: September 17, 2002
    Publication date: January 20, 2005
    Inventors: Rolf Beume, Daniela Bundschuh, Christian Weimar, Stefan-Lutz Wollin
  • Compounds with growth hormone releasing properties
    Patent number: 5990084
    Abstract: The present invention related to truncated GHRs of the general formula IK-(M).sub.x -A-B-(C).sub.w -D-E-(F).sub.z -G-(N).sub.y -L (I)which have the ability to stimulate release of endogenous growth hormone.
    Type: Grant
    Filed: April 18, 1997
    Date of Patent: November 23, 1999
    Assignee: Novo Nordisk A/S
    Inventors: Stefan Lutz Richter, Kjeld Madsen, Henning Thogersen, Nils Langeland Johansen, Ole Hvilsted Olsen, Peter Hongaard Andersen, Annette Hansen
  • Factor VII -binding reagent
    Patent number: 5859010
    Abstract: The invention relates to novel compounds that potentiate zinc ion inhibition of the activity of factor VIIa or tissue factor--factor VIIa complex having the formula Ia and Ib and pharmaceutical salts thereof as well as pharmaceutical compositions comprising said novel compounds. The invention is further related to the use of said compositions for inhibiting clotting activity, tissue factor activity and factor VIIa activity.
    Type: Grant
    Filed: June 23, 1997
    Date of Patent: January 12, 1999
    Assignee: Novo Nordisk A/S
    Inventors: Lars Christian Petersen, Ole Hvilsted Olsen, Stefan Lutz Richter, Palle Jakobsen